On Target Laboratories’ Cytalux (pafolacianine) is approved as an intravenous drug that makes ovarian cancer tissues easier to see during cytoreductive surgery.
“By supplementing current methods of detecting ovarian cancer during surgery, Cytalux offers health care professionals an additional imaging approach for patients with ovarian cancer,” said Alex Gorovets, deputy director of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?